episode 926: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses guidance for prevention and treatment of monkeypox, post-infectious symptoms among children and adolescents, profiling post-infectious syndromes of different variants, comparison of vaccine Ankara vs intradermal routes of administration, infection in vaccinated individuals treated with or without PAXLOVID, duration of symptoms with positive rapid antigen after infection, epidemiologic characteristics of monkeypox, and sequelae of post-acute infection.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Guidance for prevention & treatment of Monkeypox (CDC)
- Post-infection symptoms among children and adolescents (CDC)
- Profiling post-infection syndromes in different variants (medRxiv)
- Comparison of vaccinia Ankara (MVA) vs intradermal routes of administration (NIH)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Infection in vaccinated individuals treated with or without PAXLOVID (medRxiv)
- Duration of symptoms with positive rapid antigen after infection (J Virological Methods)
- Epidemiologic characteristics of Monkeypox (CDC)
- Sequelae of post-acute infection (ScienceDirect)
- Contribute to Floating Doctors fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 926
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv